Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy. Point mutations
in the telomerase reverse transcriptase (TERT) promoter, C228T and C250T and oncogene …

Objectives TERT rs2736100 genetic polymorphism is commonly found in human
malignancies, indicating its key role in cancer cell transformation. The aim of this study is to …

Simple Summary TERT promoter mutation has recently emerged as a promising prognostic
biomarker for aggressive papillary thyroid cancer (PTC), along with BRAF B600E mutation …

Background: The role of telomerase reverse transcriptase (TERT) promoter mutations in
differentiated thyroid cancer has been well established. These mutations have a significantly …

The role of telomerase reverse transcriptase (TERT) gene promoter mutations in the
aggressiveness of papillary thyroid cancer (PTC) remains to be further investigated. Here we …

Background The BRAF V600E and telomerase reverse transcriptase (TERT) promoter
mutations have been reported in papillary thyroid carcinoma (PTC). The aim of this …

TERT promoter mutations C228T and C250T are associated with disease aggressiveness
and poor clinical outcomes in patients with papillary thyroid carcinomas. However, very little …

Although most papillary thyroid carcinomas (PTCs) have a good prognosis, a small but
certain fraction shows aggressive behavior. Therefore, a novel and well-performing …

Background The presence of telomerase reverse transcriptase (TERT) promoter mutations
have been associated with a poor prognosis in patients with papillary thyroid carcinomas …

Several previous studies have shown that mutations in B‑Raf proto‑oncogene (BRAF) and
telomerase reverse transcriptase (TERT) can be used for the diagnosis and prognosis of …